Eupraxia Pharmaceuticals is a clinical-stage biotech developing locally delivered, extended-release medicines with its proprietary Diffusphere polymer microsphere technology. The platform is designed to release drug at the disease site in a controlled, long-lasting profile while limiting systemic exposure. Lead programs have included eosinophilic esophagitis and other conditions where prolonged local therapy could reduce dosing burden and side effects.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -8.7 | — |
| Q3 2025 | 0 | — | -6.4 | — |
| Q4 2025 | 0 | — | -16.7 | — |
| Q1 2026 | 0 | — | -12.7 | — |
| Q2 2026 | 0 | — | -14.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Idea Acquisition Corp. (IACO), D. Boral Acquisition I Corp. (DBCA), RBB Bancorp (RBB), Wellchange Holdings Company Limited (WCT), Meshflow Acquisition Corp. (MESH), Verra Mobility Corporation (VRRM)